Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Phillip Pham

Pain Medicine West Chester, OH Doctor of Osteopathy

NPI 1265633341 CMS profile 57609

7760 W Voice Of America Park Dr, Suite D, West Chester, OH 45069

Open in the dashboard

General payments

$5,270

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Phillip Pham of West Chester, OH is reported in the CMS Open Payments database as having received $5,270 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $677 39
2024 General $727 45
2023 General $1,545 52
2022 General $534 40
2021 General $454 36
2020 General $343 21
2019 General $989 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phillip Pham
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Phillip Pham were reported at $677. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Phillip Pham Pain Medicine median Middle half National median
2019 $989 $409 $115–$1,311 $163
2020 $343 $214 $66–$666 $114
2021 $454 $299 $84–$899 $132
2022 $534 $335 $103–$1,149 $149
2023 $1,545 $376 $114–$1,228 $160
2024 $727 $387 $115–$1,173 $164
2025 $677 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,310 94 payments
  2. Medtronic, Inc. $426 22 payments
  3. Boston Scientific Corporation $341 18 payments
  4. Collegium Pharmaceutical, Inc. $321 18 payments
  5. Amgen Inc. $291 12 payments
  6. SPR Therapeutics, Inc $261 1 payment
  7. Scilex Pharmaceuticals Inc. $183 14 payments
  8. Pfizer Inc. $178 10 payments
  9. Biohaven Pharmaceuticals, Inc. $162 11 payments
  10. Novartis Pharmaceuticals Corporation $162 12 payments
  11. Other $1,637 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,009 286 payments
  2. Travel and Lodging $261 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $981 55 payments
  2. UBRELVY $979 74 payments
  3. AIMOVIG $411 23 payments
  4. INTELLIS ADAPTIVESTIM $295 16 payments
  5. SPRINT PNS System $261 1 payment
  6. BELBUCA $255 14 payments
  7. NURTEC ODT Primary Care $210 14 payments
  8. WaveWriter Alpha Prime 16 $209 10 payments
  9. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $145 12 payments
  10. NURTEC ODT Pain $116 6 payments
  11. Other $2,522 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,612

Median for Pain Management: 951

Drug cost

$61,176

Median for Pain Management: $26,034

Branded share of claims

43.2%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 439 $13,154
Oxycontin Oxycodone Hcl Brand 34 $9,386
Xtampza Er Oxycodone Myristate Brand 18 $8,770
Buprenorphine Generic 34 $6,226
Movantik Naloxegol Oxalate Brand 14 $5,553
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 153 $4,837
Oxycodone Hcl Generic 205 $3,072
Gabapentin Generic 209 $2,667
Pregabalin Generic 90 $1,493
Morphine Sulfate Er Morphine Sulfate Brand 38 $850

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$124,157

Of which drugs: $11,329

Medicare patients

131

Average age 69

Services billed

16,669

85 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 44%
Diabetes 37%
Ischemic heart disease 31%
COPD 28%
Chronic kidney disease 21%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 41 670 $526
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 44 12,445 $128
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 37 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $108
$108 — —
UBRELVY
  • AbbVie, Inc. $89
$89 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $81
$81 — —
NURTEC ODT
  • PFIZER INC. $30
$30 — —
ZAVZPRET
  • PFIZER INC. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record